Safety assessment of anti-B cell maturation antigen chimeric antigen receptor T cell therapy: a real-world study based on the FDA adverse event reporting system database
This study provides a foundation for understanding the safety profile of CAR-T cell therapy, particularly in relation to the emergence of secondary malignancies. Such insights are helpful for clinical decision-making and the safe and effective utilization of these therapeutic agents.
Authors
- Bianling Feng (ORCID: https://orcid.org/0000-0003-1937-7951)
- Shuzhi Lin
- Shuang Lei
- Lin Yin
- Xiaoying Zhu (ORCID: https://orcid.org/0000-0001-8483-2661)
- Qian Liu (ORCID: https://orcid.org/0000-0001-5341-1290)
- Wei Liu (ORCID: https://orcid.org/0000-0003-2018-7004)
Institutions
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-03
- DOI
- https://doi.org/10.3389/fimmu.2024.1433075
- Citations
- 7
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.68